Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)

Pamela L. Kunz, Noah Graham, Paul J. Catalano, +16

Journal of Clinical Oncology

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial

Sara M. Tolaney, Paolo Tarantino, Noah Graham, +26

The Lancet Oncology

Breast OncologyOncologyBreast CancerAdjuvant PaclitaxelCancer Treatment +4

Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial

Nathaniel S. O’Connell, Fengmin Zhao, Ju‐Whei Lee, +13

Journal of Clinical Oncology

Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer

Joseph A. Sparano, Anne O’Neill, Noah Graham, +5

npj Breast Cancer

Factors associated with late risks of breast cancer-specific mortality in the SEER registry

José Pablo Leone, Carlos Vallejo, Michael J. Hassett, +8

Breast Cancer Research and Treatment

Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patients

Samilia Obeng‐Gyasi, Noah Graham, Shaji Kumar, +14

Blood Cancer Journal

Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer

Paolo Tarantino, Ogheneochuko Ajari, Noah Graham, +11

European Journal of Cancer

Residual DiseaseBreast OncologyHer2 ExpressionMedicinePathology +6

A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT (ECOG-ACRIN E2211).

Pamela L. Kunz, Noah Graham, Paul J. Catalano, +17

Journal of Clinical Oncology

UrologyPancreatic CancerGastrointestinal OncologyRandomized StudyMedicine +13

A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174).

Jennifer R. Eads, Noah Graham, Michael K. Gibson, +15

Journal of Clinical Oncology

Surgical OncologyEsophageal CancerGastroenterologyPathologySurgery +18

Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma

John Devin Peipert, Fengmin Zhao, Ju‐Whei Lee, +14

JAMA Network Open